Is rubicatin (rubitin) a chemotherapy drug? Drug classification and role in treatment

Lurbinectedin (Lurbinectedin), also known as rubitidine, is a new type of anti-tumor drug. Its mechanism of action is similar to traditional chemotherapy drugs, so it can be classified as a highly targeted chemotherapy drug. It belongs to an extended branch of alkylating agent anti-tumor drugs. It can specifically bind to DNA and interfere with the transcription process of cancer cells, thereby inducing cell apoptosis. This mechanism of action enables it to show significant efficacy in the treatment of a variety of solid tumors, especially small cell lung cancer and certain soft tissue sarcomas.

Unlike traditional chemotherapy drugs, rubicatin has certain targeting properties. It can preferentially act on actively transcribed cancer cells while inhibiting the function of tumor-associated macrophages, thereby regulating the tumor microenvironment. This feature gives Rubicatin greater selectivity and relatively better tolerance. In the treatment of patients with advanced or recurrent small cell lung cancer, rubicatin has been approved as a second-line treatment in many countries and has shown high response rates and the potential to extend survival.

Currently, the original drug Rubicatin has been approved for marketing in mainland China, but it has not yet been included in medical insurance and its price is relatively high. In the Hong Kong market, the price of a box of 4mg is about 2 more than 10,000 yuan; the US version is about 9 more than 10,000 yuan, and the Singapore version is about 3 more than 10,000 yuan. In addition, there are currently no generic drugs of Rubicatin on the market. If patients need to use it, they mainly rely on the original drug and should carry out individualized treatment under the guidance of a doctor.

In general, rubicatin is a new anti-cancer drug that has both a chemotherapeutic mechanism and a certain targeting effect. Although it is essentially a generalized chemotherapy drug, it is regarded as one of the new generation of "precision chemotherapy" drugs because of its more precise molecular design and mode of action and better tolerance. For patients with refractory or relapsed tumors, it provides new treatment options to extend life and improve quality of life. Whether the drug is suitable for use should be determined based on the patient's specific condition, past treatment experience, and doctor's evaluation.

Reference materials:https://www.zepzelca.com/